Article Archive
1811 articles · newest first
Sep 4, 2026 · 2 min read
SMC Corporation has committed 94.6% of the ¥50bn its board approved in May for share repurchases, spent within roughly three months of a ten-month window that does not close until March 2027.
Sep 4, 2026 · 2 min read
A quarter of the ¥32.12bn spent buying up Shikoku Electric Power shares was borrowed, and more than 10 million of the acquired shares are already pledged to two banks as collateral.
Sep 4, 2026 · 1 min read
Massachusetts Financial Services Company's combined position in the drugstore-linked retailer fell from 5.13% to 2.89% as of August 31, according to a change report filed with Japan's Kanto Local Finance Bureau.
Sep 4, 2026 · 2 min read
The trading house spent nearly its entire ¥80bn repurchase budget by September 3, 2026, seven months before the board's cutoff, and will cancel the 47.65 million shares it bought back on April 9, 2027.
Sep 4, 2026 · 3 min read
METI's draft would let it investigate a mineral supplier only when its exit risks disrupting Japan's supply, and would require certified projects to route cyberattack reports through the ministry to a Cabinet Secretariat cyber-coordination office; comments close October 4, 2026.
Sep 4, 2026 · 1 min read
Tokyo-listed services firm ZETA (6031) moved onto the Tokyo Stock Exchange's Standard market on September 4, 2026, a segment change its own notice explains with thanks to shareholders rather than any stated financial or governance rationale.
Sep 3, 2026 · 2 min read
NANKAI's ¥20bn refinancing splits into three-year notes at 2.375% and ten-year notes at 3.407%, both rated A by R&I, with net proceeds set aside to repay loans due before the end of March 2027.
Sep 3, 2026 · 2 min read
OKWEB's board has now approved reallocating ¥366mn of M&A funds to working capital, months after part of that money, ¥32mn as of end-June, had already been spent without prior board sign-off or disclosure, a gap the company blames on its management department's lapsed internal checks.
Sep 3, 2026 · 2 min read
The Shinagawa-based operator of the installed office snack service OFFICE DE YASAI priced its IPO at ¥1,600, the ceiling of its indicated range, ahead of a September 11 Tokyo debut, but venture investors and other existing shareholders are selling far more stock than the roughly ¥63.6mn the company itself raises.
Sep 3, 2026 · 2 min read
GS Yuasa Corporation plans to raise ¥10bn in its first-ever green bond, lending the entire sum to its battery subsidiary to expand domestic stationary lithium-ion production, with JCR blessing the framework against ICMA and Japanese environment-ministry green-bond guidelines.
Sep 3, 2026 · 2 min read
MLIT's draft lets EASA Category B1 holders sitting Japan's first- or second-class maintenance exam skip two practical checks with proof of high-power engine test-run authorization at an EASA-certified shop; comment runs to October 3, 2026.
Sep 3, 2026 · 2 min read
OKI's ATM joint venture with Hitachi now has a provisional name, a Tokyo headquarters address and a president and vice-president lined up from each parent, but capital remains undecided and the October 1 launch still needs antitrust and foreign-investment clearances.
Sep 3, 2026 · 2 min read
Some used trucks bought by FinTech Global's investor funds were never re-registered in the funds' name, a special probe into operator AI Storm found, and the Tokyo firm still cannot say what it will cost.
Sep 3, 2026 · 2 min read
Baudroie's fourth-largest shareholder has agreed to tender his full 3.93% stake into BCPE Neon Cayman's ¥2,970-a-share buyout, adding to a founder share sale struck at a lower price as the offeror works toward a two-thirds squeeze-out vote.
Sep 3, 2026 · 2 min read
Hikari Tsushin is refinancing maturing debt with a four-year tranche priced at 3.021% and a seven-year tranche at 3.977%, both rated A/A+ and drawn from a ¥200bn shelf programme registered in July 2025.
Sep 3, 2026 · 2 min read
JM Holdings now expects ¥198.5bn in sales for the year to July 2026, but a ¥1.04bn store impairment and cautious price increases on rising food costs cut its net profit forecast to ¥4.9bn, down 30% from the original guide.
Sep 3, 2026 · 3 min read
Comments are open until October 2 on a draft rule that would require operators to complete planned maintenance on safety-critical reactor equipment within existing outage-time limits and to verify the plan with a probabilistic risk assessment beforehand.
Sep 3, 2026 · 3 min read
A 17% holder of NIPPO Ltd. wants the company to borrow for a buyback worth up to ¥10bn at ¥4,000 a share and lift its payout ratio to 100% or more, and says it may push to dismiss directors if the board says no.
Sep 3, 2026 · 2 min read
Japan's antitrust watchdog found Nichirin left 25 subcontractors storing 1,048 molds and jigs for up to 22 months without orders or compensation, and has ordered the automotive-hose maker to settle any remaining balance beyond the ¥9.79mn it already paid.
Sep 3, 2026 · 2 min read
Partners Life, the Auckland insurer Daiichi Life fully owns, has agreed to pay NZ$630mn for Fidelity Life, taking the business from Guardians of New Zealand Superannuation, Ngāi Tahu Investments and other holders, with completion targeted for March to July 2027 subject to regulatory approval.
Sep 3, 2026 · 3 min read
A foreign investor's review of six Japanese issuers for the FSA's Disclosure Working Group found only six of 103 risk factors carried a number and filings sometimes reached shareholders a week before the vote; the submission argues merging the business report into the Yuho fixes none of that.
Sep 3, 2026 · 3 min read
Lumina Japan Acquisition paid ¥165bn in cash, no borrowing, for a 72% stake in Nippon Sheet Glass at ¥450 a share, then pledged those same shares to a fourteen-bank lender group tied to refinancing the glassmaker's debt ahead of a September 30 squeeze-out.
Sep 3, 2026 · 2 min read
Five amended securities reports filed on the same day show the medical-equipment distributor's disclosed lease commitments were too low every year from mid-2020 to mid-2025, in one year by more than a billion yen.
Sep 3, 2026 · 2 min read
China's NMPA cleared the self-injected, once-weekly formulation of Leqembi as first-line therapy, the second market after the US to allow at-home dosing for a disease that has mostly meant fortnightly hospital infusions.